依维莫司联合贝伐珠单抗治疗复发性卵巢、腹膜和输卵管癌的II期研究
这项开放标签、单中心II期试验纳入50例复发性卵巢、腹膜和输卵管癌患者,给予依维莫司10 mg/日口服联合贝伐珠单抗10 mg/kg静脉每14天一次(28天周期)。6个月无进展生存率为26%(校正后24%,95%CI 16.67-42.71%)。作者认为联合方案较单用贝伐珠单抗未明显改善缓解,但PI3K/mTOR通路改变的患者可能获益,需进一步研究。
要点
- 6个月无进展生存率为26%(校正后24%,95%CI 16.67-42.71%)。
- 1例完全缓解,6例部分缓解,35例最佳疗效为疾病稳定。
- 25例患者发生2例4级和31例3级毒性,常见口腔黏膜炎、乏力、腹泻、高血压等。
核心结论
- 依维莫司联合贝伐珠单抗较单用贝伐珠单抗未明显改善缓解,但PI3K/mTOR通路改变的选择性患者可能获益,需进一步研究。
研究设计与样本
- 开放标签、单中心II期试验,纳入50例复发性卵巢、腹膜和输卵管癌患者,中位年龄60.5岁(范围28-82)。
- 给药方案为依维莫司10 mg/日口服联合贝伐珠单抗10 mg/kg静脉每14天一次,28天为一周期,治疗持续至疾病进展或不良事件。
主要发现
- 46例(92%)有可测量病灶;13例(26%,校正后24%)在6个月时无进展(95%CI 16.67-42.71%)。
- 最佳疗效为1例完全缓解、6例部分缓解、35例疾病稳定。
- 铂敏感和铂耐药患者均观察到缓解,部分既往接受过贝伐珠单抗者也观察到缓解。
- 25例不同患者中记录到2例4级和31例3级毒性,常见毒性包括口腔黏膜炎、乏力、腹泻、高血压、疼痛、恶心和厌食。
- 38例(76%)因疾病进展退出研究;长期缓解者中鉴定出独特的分子谱。
关键数值与推荐
- 主要终点6个月无进展生存率为26%(校正后24%,95%CI 16.67-42.71%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent ovarian, fallopian tube, and peritoneal cancers have limited potential for cure with traditional therapies. Preliminary results from a phase I study of everolimus and bevacizumab in advanced solid tumors showed it to be a promising combination. The primary objective of this study was to evaluate the 6-month progression-free survival for everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. Secondary objectives included evaluation of efficacy and safety. METHODS: In this open-label, single-institution, phase II trial, patients received everolimus 10 mg/day by mouth and bevacizumab 10 mg/kg intravenously every 14 days on a 28-day cycle. Treatment continued until disease progression or adverse event. RESULTS: Fifty patients were enrolled. Median age was 60.5 years (range 28-82). Forty-six (92%) subjects had measurable disease. Thirteen (26%) (24% adjusted) were progression-free at 6 months (95% CI 16.67-42.71%). One patient had a complete response, while six had a partial response and 35 had stable disease as their best response. Patients with both platinum-sensitive and -resistant disease demonstrated responses, as did some prior bevacizumab exposure. There were two grade 4 and 31 grade 3 toxicities noted in 25 distinct patients. The most common reported toxicities included oral mucositis, fatigue, diarrhea, hypertension, pain, nausea and anorexia. Thirty-eight (76%) patients came off study because of disease progression. Unique molecular profiles were identified in long-term responders. CONCLUSIONS: Combining everolimus and bevacizumab does not distinctly improve response compared to bevacizumab alone, but further study of selected patients with alterations in the PI3K/mTOR pathway may document benefit.
引用
- Taylor SE, Chu T, Elvin JA, et al. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. Gynecol Oncol. 2019. PMID: 31739991. doi:10.1016/j.ygyno.2019.10.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。